I Upgraded My Period Routine With These Toxin-Free Products, and They're On Sale Through Prime Day
That's when I switched to Viv, a toxin-free, sustainable menstrual care brand whose products actually work. I've tried all of the brand's products, from the organic cotton pads to the tampons with BPA-free applicators to the surprisingly comfortable menstrual cup.
Right now, Viv is offering 25% off all menstrual cups and 15% off pads and tampons for Prime Day. If you're curious about a cleaner period routine, this is the chance to start or stock up.
Check out our CNET live deals for staff-approved wellness, tech and home picks.
Hey, did you know? CNET Deals texts are free, easy and save you money
Why I love Viv
Viv's products have completely changed how I feel about my period. The tampons are made with 100% organic cotton and come in certified compostable corn starch-based wrappers instead of plastic. The pads are made from bamboo, corn fibers and wood pulp. They are also naturally antibacterial and a lot better for the environment. The disc, which I find doesn't leak like other menstrual cups, is made from medical-grade silicone and is pretty comfortable. The brand has become my go-to for cleaner, lighter menstrual products.
I don't dread buying or using period products anymore. Viv has helped me feel more aligned with how I want to care for my body, with clean and intentional products that are good for me and the planet.
Why this deal matters
Swapping your period products can feel intimidating, and honestly, really expensive -- especially with reusable cups. That's why this up to 25% off deal is great for making the switch. If you want to go toxin-free or reduce your period waste, Viv makes the transition much easier and more affordable.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Wells Fargo Cuts Elevance (ELV) Price Target on Margin Uncertainty
Elevance Health, Inc. (NYSE:ELV) ranks among the . Wells Fargo kept its Overweight rating on Elevance Health, Inc. (NYSE:ELV) on July 15, but lowered its price target on the health insurer from $478 to $400. Wells Fargo applied a lower multiple of 10.5x to its 2026 earnings per share projection of $38.05, which is less than the previous multiple of 11.5x. designer491/ Wells Fargo stated that the primary driver of the reduced value multiple was uncertainty regarding margins in the Medicaid, Medicare Advantage (MA), and Health Insurance Exchange (HIX) segments for 2025. The firm also pointed out that there was 'relatively low visibility to improvement in 2026,' especially in the Medicaid and Health Insurance Exchange segments. However, it insisted that Elevance's valuation 'remains compelling once dust settles on estimates.' Elevance Health, Inc. (NYSE:ELV), previously Anthem, Inc., is a leading health-benefits provider in the United States. The company offers medical, pharmaceutical, dental, long-term care, disability, and behavioral health insurance under numerous brands, including Anthem Blue Cross, Blue Shield, Wellpoint, and Carelon. While we acknowledge the potential of ELV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Hulk Hogan Underwent 25 Surgeries Before His Heartbreaking Death
Hulk Hogan Underwent 25 Surgeries Before His Heartbreaking Death originally appeared on Parade. Wrestling icon Hulk Hogan has died at the age of 71, following a reported cardiac arrest. The shocking news comes after Hogan opened up about his declining health and the toll his legendary wrestling career had taken on his body. Hulk Hogan Had 25 Surgeries in 10 Years In a September 2024 appearance on Logan Paul's 'IMPAULSIVE' podcast, Hogan revealed that he had undergone a staggering 25 surgeries over the past decade. 'I've had like 25 surgeries in the last ten years. Ten of them were back surgeries,' Hogan told Paul. 'Nobody told me this gimmick stuff was fake. I've had 10 back surgeries, both knees and both hips replaced, shoulders — everything.' The WWE Hall of Famer also reflected on the physically punishing early days of professional wrestling. He recalled how Andre the Giant once warned him about the dangerous condition of older wrestling rings. 'The equipment back in the day when I started wrestling in '77 was a little different than the rings and stuff you guys are working in now,' Hogan said. 'Andre used to tell me, 'Boss, don't fall down. You won't get back up.' It was like a 22-foot boxing ring that had lumps in it, boards sticking up—it was horrible.' Hulk Hogan's Health Issues Before His Death In the months leading up to his death, Hogan's public appearances sparked concern among fans. After appearing on Fox & Friends to promote his new wrestling league, many noted the WWE icon looked 'unwell.' Soon after, Hogan was reportedly hospitalized for neck and back issues, undergoing a minor cervical fusion surgery. Rumors quickly spread that he was on his 'deathbed,' but his representatives shut down those claims. 'He just needs from time to time a medical check-up,' a spokesperson reportedly told The Independent, adding there were 'no reasons to panic.' Hulk Hogan's Cause of Death: Cardiac Arrest Reported As of now, Hogan's cause of death is being reported as cardiac arrest, though official confirmation and more details are expected in the coming days. Hulk Hogan Underwent 25 Surgeries Before His Heartbreaking Death first appeared on Parade on Jul 24, 2025 This story was originally reported by Parade on Jul 24, 2025, where it first appeared.
Yahoo
an hour ago
- Yahoo
Cogent Biosciences Rated as a Buy at Citi on Robust Pipeline
Cogent Biosciences, Inc. (NASDAQ:COGT) is one of the best biotech stocks to buy according to billionaire Steve Cohen. On July 18, Citi raised its price target of the stock to $22 from $15 while maintaining a 'Buy' rating. A doctor reading the results of a Phase 2 clinical trial of treatments for cancer, infectious diseases and autoimmune and inflammatory diseases. The price target hike comes as the company delivers top-line results from bezuclastinib (bezu) in non-advanced systemic mastocytosis (NonAdvSM). According to Citi, investors are increasingly viewing bezuclastinib as an improvement over Blueprint's Ayvakit. The research firm expects the company to deliver positive symptom and biomarker data at ASH in December. Beyond bezuclastinib, Cogent Biosciences is also advancing its other pipeline candidates. The company plans to release advanced systemic mastocytosis (AdvSM) data from the APEX trial in the second half of the year. It will also provide results from the PEAK trial for gastrointestinal stromal tumors (GIST). Cogent Biosciences, Inc. (NASDAQ:COGT) is a biotechnology company that develops precision therapies for genetically defined diseases. It focuses on diseases caused by genetic mutations. Its lead program, bezuclastinib, is a tyrosine kinase inhibitor designed to target the KIT D816V mutation, which drives systemic mastocytosis, as well as other mutations in KIT exon 17. While we acknowledge the potential of COGT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Goldman Sachs REIT Stocks: Top 12 Stock Picks. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
